Neoadjuvant Endocrine Therapy: Who Benefits Most?

Julie Grossman; Cynthia Ma; Rebecca Aft

doi:10.1016/j.soc.2017.07.008

Neoadjuvant Endocrine Therapy: Who Benefits Most?

Julie Grossman
, Cynthia Ma
, Rebecca Aft

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

Original language	English
Pages (from-to)	121-140
Number of pages	20
Journal	Surgical Oncology Clinics of North America
Volume	27
Issue number	1
DOIs	https://doi.org/10.1016/j.soc.2017.07.008
State	Published - Jan 2018

Keywords

Aromatase inhibitors
Estrogen receptor–positive breast cancer
Neoadjuvant chemotherapy
Neoadjuvant endocrine therapy

Access to Document

10.1016/j.soc.2017.07.008

Cite this

@article{ac66004177224afd88b73e7d53f08ba5,

title = "Neoadjuvant Endocrine Therapy: Who Benefits Most?",

abstract = "Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor{\textendash}positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor{\textendash}positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.",

keywords = "Aromatase inhibitors, Estrogen receptor{\textendash}positive breast cancer, Neoadjuvant chemotherapy, Neoadjuvant endocrine therapy",

author = "Julie Grossman and Cynthia Ma and Rebecca Aft",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = jan,

doi = "10.1016/j.soc.2017.07.008",

language = "English",

volume = "27",

pages = "121--140",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

number = "1",

}

TY - JOUR

T1 - Neoadjuvant Endocrine Therapy

T2 - Who Benefits Most?

AU - Grossman, Julie

AU - Ma, Cynthia

AU - Aft, Rebecca

PY - 2018/1

Y1 - 2018/1

N2 - Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

AB - Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

KW - Aromatase inhibitors

KW - Estrogen receptor–positive breast cancer

KW - Neoadjuvant chemotherapy

KW - Neoadjuvant endocrine therapy

UR - https://www.scopus.com/pages/publications/85034228562

U2 - 10.1016/j.soc.2017.07.008

DO - 10.1016/j.soc.2017.07.008

M3 - Review article

C2 - 29132556

AN - SCOPUS:85034228562

SN - 1055-3207

VL - 27

SP - 121

EP - 140

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 1

ER -

Neoadjuvant Endocrine Therapy: Who Benefits Most?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this